echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dizhe Pharmaceuticals DZD8586 obtained the approval notice for drug clinical trials from the State Food and Drug Administration

    Dizhe Pharmaceuticals DZD8586 obtained the approval notice for drug clinical trials from the State Food and Drug Administration

    • Last Update: 2022-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of January 5, Dizhe Pharmaceuticals announced that the company has received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Drug Administration for DZD8586, and agreed to approve the development of relapsed and refractory B cell non-Hodgkin drugs in China.
    Clinical trials in Chikin's lymphoma
    .

    DZD8586 is an oral, highly selective, small molecule targeted drug that can penetrate the blood-brain barrier independently developed by the company.
    It is a global innovative drug developed by the company based on the core technology platform of translational science for the treatment of tumors and other It has been approved by the State Food and Drug Administration to conduct clinical trials for relapsed and refractory B-cell non-Hodgkin lymphoma (NHL)
    .


    Preclinical studies have shown that DZD8586 has met the design expectations for all the drug indicators, has good safety and the ability to penetrate the blood-brain barrier, and can effectively inhibit the growth of B-cell non-Hodgkin's lymphoma cells


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.